Giuseppe
Emeritus
[Source: Eurosurveillance, full page: (LINK). Abstract, edited.]
Eurosurveillance, Volume 18, Issue 40, 03 October 2013
Research articles
Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007
L F Anderson <SUP>1</SUP>, S Tamne<SUP>1</SUP>, J P Watson<SUP>2</SUP>, T Cohen<SUP>3</SUP>, C Mitnick<SUP>4</SUP>, T Brown<SUP>5</SUP>, F Drobniewski<SUP>5</SUP>, I Abubakar<SUP>1</SUP><SUP>,6</SUP>
<SUP></SUP>
<SUP>1</SUP>Public Health England, Respiratory Diseases Department, TB Section, London, United Kingdom; 2 Department of Respiratory Medicine, Leeds General Infirmary, Leeds, United Kingdom; 3 Department of Epidemiology, Harvard School of Public Health, Boston, United States; 4 Department of Global Health & Social Medicine, Harvard Medical School, United States; 5 Public Health England, National Mycobacterial Reference Laboratory, Centre for Immunology and Infectious Disease, Barts and The London School of Medicine and Dentistry, London, United Kingdom; 6 Research Department of Infection and Population Health, University College London, London, United Kingdom
_____
Citation style for this article: Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill. 2013;18(40)
ii=20601. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20601
Date of submission: 04 September 2012
_____
United Kingdom (UK) guidelines recommend at least 18 months treatment for patients with multidrug-resistant tuberculosis (MDR-TB). Prior to 2008, data on treatment outcome were only available at 12 months and therefore the proportion completing treatment was unknown. This retrospective-prospective cohort study reports on treatment outcomes for MDR-TB patients notified between 2004 and 2007 and examines factors associated with successful outcomes. 70.6% (144/204) completed treatment in 24 months or more, 6.9% (14) stopped treatment, 6.9% (14) died, 7.8% (16) were lost to follow up, 0.5% (1) relapsed and 4.4% (9) were transferred overseas. Following adjustment for age, being non-UK born, non-compliance and having co-morbidities, treatment with a fluoroquinolone (OR 3.09; 95% CI 1.21-7.88; p<0.05) or bacteriostatic drug (OR 4.23; 95% CI 1.60-11.18; p<0.05) were independently associated with successful treatment outcome. Treatment completion for MDR-TB cases remains below the World Health Organization (WHO) target. Our findings support current WHO guidelines for MDR-TB treatment. The UK should consider adopting individualised regimens based on WHO recommended drugs, taking into account drug sensitivities. Improving treatment completion rates will be key to tackling further drug resistance and transmission from untreated infectious cases.
-
-------
Eurosurveillance, Volume 18, Issue 40, 03 October 2013
Research articles
Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007
L F Anderson <SUP>1</SUP>, S Tamne<SUP>1</SUP>, J P Watson<SUP>2</SUP>, T Cohen<SUP>3</SUP>, C Mitnick<SUP>4</SUP>, T Brown<SUP>5</SUP>, F Drobniewski<SUP>5</SUP>, I Abubakar<SUP>1</SUP><SUP>,6</SUP>
<SUP></SUP>
<SUP>1</SUP>Public Health England, Respiratory Diseases Department, TB Section, London, United Kingdom; 2 Department of Respiratory Medicine, Leeds General Infirmary, Leeds, United Kingdom; 3 Department of Epidemiology, Harvard School of Public Health, Boston, United States; 4 Department of Global Health & Social Medicine, Harvard Medical School, United States; 5 Public Health England, National Mycobacterial Reference Laboratory, Centre for Immunology and Infectious Disease, Barts and The London School of Medicine and Dentistry, London, United Kingdom; 6 Research Department of Infection and Population Health, University College London, London, United Kingdom
_____
Citation style for this article: Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill. 2013;18(40)
ii=20601. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20601 Date of submission: 04 September 2012
_____
United Kingdom (UK) guidelines recommend at least 18 months treatment for patients with multidrug-resistant tuberculosis (MDR-TB). Prior to 2008, data on treatment outcome were only available at 12 months and therefore the proportion completing treatment was unknown. This retrospective-prospective cohort study reports on treatment outcomes for MDR-TB patients notified between 2004 and 2007 and examines factors associated with successful outcomes. 70.6% (144/204) completed treatment in 24 months or more, 6.9% (14) stopped treatment, 6.9% (14) died, 7.8% (16) were lost to follow up, 0.5% (1) relapsed and 4.4% (9) were transferred overseas. Following adjustment for age, being non-UK born, non-compliance and having co-morbidities, treatment with a fluoroquinolone (OR 3.09; 95% CI 1.21-7.88; p<0.05) or bacteriostatic drug (OR 4.23; 95% CI 1.60-11.18; p<0.05) were independently associated with successful treatment outcome. Treatment completion for MDR-TB cases remains below the World Health Organization (WHO) target. Our findings support current WHO guidelines for MDR-TB treatment. The UK should consider adopting individualised regimens based on WHO recommended drugs, taking into account drug sensitivities. Improving treatment completion rates will be key to tackling further drug resistance and transmission from untreated infectious cases.
-
-------